Background And Objectives: Patients undergoing hemodialysis with a frequency other than thrice weekly are not included in current clinical performance metrics for dialysis adequacy. The weekly standard Kt/V incorporates treatment frequency, but there are limited data on its association with clinical outcomes.
Design, Setting, Participants, & Measurements: We used multivariable regression to examine the association of dialysis standard Kt/V with BP and metabolic control (serum potassium, calcium, bicarbonate, and phosphorus) in patients incidental to dialysis treated with home (=2373) or in-center hemodialysis (=109,273). We further used Cox survival models to examine the association of dialysis standard Kt/V with mortality, hospitalization, and among patients on home hemodialysis, transfer to in-center hemodialysis.
Results: After adjustment for potential confounders, patients with dialysis standard Kt/V <2.1 had higher BPs compared with patients with standard Kt/V 2.1 to <2.3 (3.4 mm Hg higher [<0.001] for home hemodialysis and 0.9 mm Hg higher [<0.001] for in-center hemodialysis). There were no clinically meaningful associations between dialysis standard Kt/V and markers of metabolic control, irrespective of dialysis modality. There was no association between dialysis standard Kt/V and risk for mortality, hospitalization, or transfer to in-center hemodialysis among patients undergoing home hemodialysis. Among patients on in-center hemodialysis, dialysis standard Kt/V <2.1 was associated with higher risk (adjusted hazard ratio, 1.11; 95% confidence interval, 1.07 to 1.14) and standard Kt/V ≥2.3 was associated with lower risk (adjusted hazard ratio, 0.97; 95% confidence interval, 0.94 to 0.99) for death compared with standard Kt/V 2.1 to <2.3. Additional analyses limited to patients with available data on residual kidney function showed similar relationships of dialysis and total (dialysis plus kidney) standard Kt/V with outcomes.
Conclusions: Current targets for standard Kt/V have limited utility in identifying individuals at increased risk for adverse clinical outcomes for those undergoing home hemodialysis but may enhance risk stratification for in-center hemodialysis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967669 | PMC |
http://dx.doi.org/10.2215/CJN.05680517 | DOI Listing |
J Nephrol
January 2025
Nephrology Unit, V. Fazzi Hospital, Lecce, Italy.
Background: The KDIGO recommendation in acute kidney injury (AKI) patients requiring kidney replacement therapy is to deliver a Urea Kt/V of 1.3 for intermittent thrice weekly hemodialysis, and an effluent volume of 20-25 ml/kg/hour when using continuous renal replacement therapy (CRRT). Considering that prior studies have suggested equivalent outcomes when using CRRT-prolonged intermittent renal replacement therapy (PIRRT) effluent doses below 20 mL/kg/h, our group investigated the possible benefits of low effluent volume CRRT-PIRRT (12.
View Article and Find Full Text PDFTher Apher Dial
January 2025
Department of Nephrology, The Third Clinical Medical College of China Three Gorges University, Sinopharm Gezhouba Central Hospital, Yichang, China.
Introduction: Transcutaneous auricular vagus nerve stimulation (tVNS) has shown potential in neurological, autoimmune, and cardiovascular disorders, but its effects on HD patients remain unclear. This study aimed to evaluate the efficacy and safety of tVNS in HD patients.
Methods: We conducted a randomized controlled clinical trial on patients receiving HD ≥6 months.
Cureus
October 2024
Central Clinical Laboratory, University Hospital St. Marina, Varna, BGR.
Introduction One of the most important critical determinants of quality of life and adequacy of hemodialysis (HD) performed in patients is the recorded survival and mortality rates. Nowadays, as an adequately performed HD dialysis, we accept the one with reaching values for the index single pool Kt/V (spKt/V) higher than 1.2.
View Article and Find Full Text PDFRen Fail
December 2024
Department of Nephrology, Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai Municipality, China.
Background: Adequate delivery of hemodialysis (HD), measured by the spKt/V derived from urea reduction, is an important determinant of clinical outcomes in chronic hemodialysis patients. However, the need for pre- and postdialysis blood samples prevented the assessment of spKt/V in every session.
Methods: This retrospective single-center study was performed on end-stage renal disease (ESKD) patients aged ≥ 18 years who received standard thrice-weekly chronic HD therapy.
BMC Nephrol
October 2024
Renal Research Division, AURAL, 5 rue Henri Bergson, Strasbourg, 67087, France.
Patients with chronic kidney disease (CKD) on dialysis have a higher mortality rate associated with SARS-CoV-2 infection. Although vaccines are now available, the protective response rates and determinants of humoral response to the vaccine are poorly described in patients on peritoneal dialysis. This was a prospective observational study describing the response rates of detectable and standardized protective antibody titers one month after each mRNA vaccine dose in a cohort of 88 patients on peritoneal dialysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!